Yesterday’s announcement is a function of the process that has nothing to do with AGM timing. Same will largely go for any Infusion sale or TAVR partnership deal to some extent, because as you say management have SIO and SB calling the shots on resolution 1.
And I’m sure those 2 would be kept up to speed on how the business is traveling.
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-96
-
- There are more pages in this discussion • 472 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.75 |
Change
-0.110(1.01%) |
Mkt cap ! $227.2M | |||
| Open | High | Low | Value | Volume |
| $10.95 | $10.95 | $10.24 | $285.2K | 26.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $10.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.75 | 413 | 1 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |